Review
Cell & Tissue Engineering
Faroogh Marofi, Marwan Mahmood Saleh, Heshu Sulaiman Rahman, Wanich Suksatan, Moaed E. Al-Gazally, Walid Kamal Abdelbasset, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Ali Hassanzadeh, Mahboubeh Yazdanifar, Roza Motavalli, Yashwant Pathak, Adel Naimi, Behzad Baradaran, Marzieh Nikoo, Farhad Motavalli Khiavi
Summary: CAR-NK cells are safer and more efficient than CAR-T cells in treating tumors, especially hematological malignancies. NK cells can be effectively engineered to express CARs with substantial cytotoxic activity against both hematological and solid tumors.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Immunology
Ayda Baghery Saghchy Khorasani, Amir-Mohammad Yousefi, Davood Bashash
Summary: CAR NK cells have attracted attention as a viable alternative to CAR T cells due to their MHC-independency, shorter life expectancy, potential for off-the-shelf immune product creation, and potent antitumor properties. This article provides an updated review of the differences between CAR T and CAR NK cells, current enhancements in CAR NK design, sources for collecting NK cells, and strategies for transducing CARs to NK cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Zhihuan Yang, Ying Wang
Summary: Cellular therapies, particularly CAR-T cell therapy, have revolutionized the treatment of hematological malignancies. Both China and the United States have made significant contributions to the development of clinical trials for CAR-T cell therapy. However, there are still limitations such as high relapse rates and adverse side effects. Different approaches are being explored in clinical trials to address these issues and promising breakthroughs have been made.
CHINESE MEDICAL JOURNAL
(2023)
Article
Immunology
Maren Soldierer, Arthur Bister, Corinna Haist, Aniththa Thivakaran, Sevgi Can Cengiz, Stephanie Sendker, Nina Bartels, Antonia Thomitzek, Denise Smorra, Maryam Hejazi, Markus Uhrberg, Kathrin Scheckenbach, Cornelia Monzel, Constanze Wiek, Dirk Reinhardt, Naghmeh Niktoreh, Helmut Hanenberg
Summary: The success of CAR T cells has opened new possibilities for immunotherapy of hematological malignancies. Genetically modifying NK cells as alternative CAR immune effector cells shows promise, but challenges still exist in manufacturing suitable CAR NK cell products.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Long Chen, Fukun Chen, Huatao Niu, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Rong Huang, Ke Li, Yujie Lei, Yunchao Huang
Summary: CAR-T cell therapy is a novel immunotherapy strategy that has been successfully used against both hematological tumors and solid tumors. Despite some challenges, CAR-T cell treatment still holds great promise.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Samane Abbasi, Milad Asghari Totmaj, Masoumeh Abbasi, Saba Hajazimian, Pouya Goleij, Javad Behroozi, Behrouz Shademan, Alireza Isazadeh, Behzad Baradaran
Summary: Over the last decade, novel therapeutic approaches like CAR-T-cell immunotherapy have transformed the treatment perspective of human malignancies. However, this therapy is associated with side effects and faces challenges in manufacturing, engineering, applications, and toxicities. Further studies are needed to enhance efficacy and minimize adverse events.
Article
Multidisciplinary Sciences
Chao Wang, Jianpeng Wang, Shusheng Che, Hai Zhao
Summary: For many years, the main methods of cancer treatment have been surgery, chemotherapy, and radiation therapy. However, these methods often have limited success. Immunotherapy, particularly CAR-T therapy, has emerged as a promising approach for treating tumors. CAR-T therapy uses the patient's own T cells to target and kill tumor cells, showing significant success in the treatment of hematological tumors.
Letter
Oncology
Ruihao Huang, Qin Wen, Xi Zhang
Summary: CAR-NK cell therapy has the advantages of low side effects and cost. However, limited antitumor effects and proliferative capacity hinder its clinical outcomes. Recent progress in engineering, target design, and combination therapy has been made for CAR-NK cell therapy, especially in treating relapsed or refractory hematological malignancies like acute myeloid leukemia and multiple myeloma. This correspondence provides a summary of the preclinical and clinical updates of universal CAR-NK cell therapy reported at the ASH 2022 annual meeting.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Lara Herrera, Silvia Santos, Miguel Angel Vesga, Tomas Carrascosa, Juan Carlos Garcia-Ruiz, Antonio Perez-Martinez, Manel Juan, Cristina Eguizabal
Summary: CAR-T cells have shown promising results in treating relapsed or refractory hematological cancers, but their limitations have led to the emergence of CAR-NK cells as a good alternative. CAR-NK cells demonstrate efficacy with fewer side-effects, positioning them as a viable option for CAR-based treatments.
Review
Oncology
Hui Lu, Xiaoyan Zhao, Ziying Li, Yu Hu, Huafang Wang
Summary: The approval of CD19 CAR-engineered T cell products in B-cell malignancies is a breakthrough in CAR-T cell immunotherapy. However, limitations such as GVHD and other adverse effects restrict their wider applications. CAR-NK cells, with their unique characteristics, are considered promising candidates for cellular immunotherapy, offering potential off-the-shelf products for immediate clinical use without HLA-matching restrictions. Researchers are shifting focus from CAR-T cells to CAR-NK cells, discussing their advantages and challenges in clinical applications.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Loredana Cifaldi, Ombretta Melaiu, Roberto Giovannoni, Monica Benvenuto, Chiara Focaccetti, Daniela Nardozi, Giovanni Barillari, Roberto Bei
Summary: DNAM-1 is a crucial NK cell activating receptor that contributes significantly to the killing of tumor or virus-infected cells by binding to specific ligands, alongside NKG2D and NCRs. DNAM-1 specifically recognizes PVR and Nectin-2 ligands expressed on a wide range of tumor cells and virus-infected cells. Although NK cells engineered with different antigen chimeric receptors or chimeric NKG2D receptors have been extensively studied, the use of DNAM-1 chimeric receptor-engineered NK cells has only been proposed in a recent proof-of-concept study. This perspective study aims to explain the rationale behind using this novel tool as a new anti-cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Bailin He, Qiusui Mai, Yunyi Pang, Shikai Deng, Yi He, Rongtao Xue, Na Xu, Hongsheng Zhou, Xiaoli Liu, Li Xuan, Chengyao Li, Qifa Liu
Summary: CD19 CAR engineered memory-like NK cells exhibit enhanced persistence and antitumor activity against CD19(+) tumors, providing a potential approach to treat patients with relapsed or refractory B cell malignancies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli, Ugo De Giorgi
Summary: To date, various therapeutic strategies, including immunotherapies, have been successful in prolonging the survival of breast cancer patients. Our article focuses on the application of chimeric antigen receptor-based immunotherapy in breast cancer.
Review
Oncology
Antonio Tapia-Galisteo, Luis alvarez-Vallina, Laura Sanz
Summary: Immune cell engagers are modified antibodies that have one arm binding a tumor-associated antigen and another arm binding an activating receptor in immune effector cells. These engagers have the potential to revolutionize the treatment of hematological malignancies and are more potent than conventional monoclonal antibodies. The field is growing rapidly, with multiple formats and targets currently in clinical trials, and trispecific antibodies show even more promise by targeting additional tumor-associated antigens or costimulatory receptors.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Immunology
Xiaomin Zhang, Lingling Zhu, Hui Zhang, Shanshan Chen, Yang Xiao
Summary: CAR-T cell therapy has shown significant success in the treatment of hematological malignancies, but challenges remain in terms of adverse events and resistance mechanisms.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Medicinal
Nazanin Mohammadipoor, Fatemeh Shafiee, Amirabbas Rostami, Mohammad Saeed Kahrizi, Hamidreza Soleimanpour, Majid Ghodsi, Mohammad Javed Ansari, Dmitry Olegovich Bokov, Behrooz Jannat, Erfan Mosharkesh, Mohammad Sadegh Pour Abbasi
Summary: A systematic review and meta-analysis found that resveratrol supplementation significantly improves endothelial function, which is particularly important for patients with cardiovascular diseases.
PHYTOTHERAPY RESEARCH
(2022)
Review
Reproductive Biology
Ahmad Saburi, Mohammad Saeed Kahrizi, Navid Naghsh, Hasti Etemadi, Ahmet Ilhan, Ali Adili, Shadi Ghoreishizadeh, Rozita Tamjidifar, Morteza Akbari, Gulinnaz Ercan
Summary: Ovarian cancer is a common malignant tumor in women and is one of the leading causes of cancer-related death in this group. Chemotherapy is the main treatment option, but drug resistance can worsen the outcome. Understanding the role of microRNAs in chemotherapy resistance can help develop new strategies for treatment.
JOURNAL OF OVARIAN RESEARCH
(2022)
Article
Multidisciplinary Sciences
Maryam Darvish, Navid Nasrabadi, Farnoush Fotovat, Setareh Khosravi, Mehrdad Khatami, Samira Jamali, Elnaz Mousavi, Siavash Iravani, Abbas Rahdar
Summary: Zn-doped CuFe2O4 nanoparticles were synthesized using plant extract and showed good cytotoxicity against lung cancer cells.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Faezeh Sharafi, Sadegh Abaei Hasani, Samira Alesaeidi, Mohammad Saeed Kahrizi, Ali Adili, Shadi Ghoreishizadeh, Navid Shomali, Rozita Tamjidifar, Ramin Aslaminabad, Morteza Akbari
Summary: ICIs have been developed and shown potential advantages in treating HCC. ICIs targeting PD-1, PD-L1, and CTLA-4 have made significant advances in HCC treatment. Several ICIs are currently being tested in clinical trials, and the field is rapidly developing. Up-to-date management guidelines are crucial for the safety profile of ICIs as immunotherapy-related adverse events expand.
CANCER CELL INTERNATIONAL
(2022)
Article
Engineering, Environmental
Samira Alesaeidi, Mohammad Saeed Kahrizi, Anahita Ghorbani Tajani, Hamed Hajipour, Marjan Ghorbani
Summary: A Soy protein/Alginate/Hydroxyapatite (SAHA) composite hydrogel was successfully formulated in this study. The incorporation of Hydroxyapatite (HA) improved the mechanical properties and thermal stability of the biopolymer-based hydrogel, making it suitable for tissue engineering applications.
JOURNAL OF POLYMERS AND THE ENVIRONMENT
(2023)
Article
Medicine, Research & Experimental
Yasaman Kargar-sichani, Mohammad Hossein Mohammadi, Vahid Amiri, Mohyedin Barzegar, Ali Keshavarz, Davood Bashash, Mehdi Allahbakhshian Farsani
Summary: This study investigated the impact of AML-derived extracellular vesicles (EVs) on the characterization of bone marrow mesenchymal stromal cells (BM-MSCs). The results showed that AML-EVs influenced the MSCs characteristics in a concentration-dependent manner. MSCs treated with a 40 μg/mL dose of EVs exhibited higher viability, increased Ki-67 and BCL-2 expression, and lower ROS levels. RT-qPCR analysis revealed significant upregulation of IL-6, Gas-6, and Galectin-3 expression in MSCs treated with a 40 μg/mL dose of EVs.
ARCHIVES OF MEDICAL RESEARCH
(2023)
Review
Microbiology
Naser Alizadeh, Ghazal Naderi, Mohammad Saeed Kahrizi, Tannaz Haghgouei, Ahmad Mobed, Mehran Ebrahimi Shah-abadi
Summary: The relationship between gut microbiota and pain has gained attention, with evidence suggesting that microbiota is an important pain modulator in the central and peripheral nervous systems. Changes in microbiota through diet or antibiotic mediation may offer a novel therapeutic strategy for pain management.
CURRENT MICROBIOLOGY
(2023)
Article
Hematology
Sharareh Mizani, Ali Keshavarz, Nader Vazifeh Shiran, Davood Bashash, Mehdi Allahbakhshian Farsani
Summary: The increased metabolism in acute myeloid leukemia (AML) malignant cells leads to the production of high levels of free radicals, causing oxidative stress conditions. This study examines the expression of SIRT1, FOXO3a, and antioxidant enzymes in AML patients and reveals their significant increase compared to healthy controls. The correlation between the expression of SIRT1 and FOXO3a genes suggests their importance in increased oxidative stress resistance of cancer cells.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2023)
Article
Biochemistry & Molecular Biology
Mohammadsaleh Jahangir, Mohammad Saeed Kahrizi, Mohammad Natami, Raziyeh Moaref Pour, Shadi Ghoreishizadeh, Maryam Hemmatzadeh, Hamed Mohammadi, Navid Shomali, Siamak Sandoghchian Shotorbani
Summary: This study investigated the role of miR-155 and its targeted factors in the pathogenesis of ankylosing spondylitis (AS). The results showed that the up-regulation of miR-155 led to the down-regulation of SOCS3 and increased expression of IL-21 and STAT3. In addition, the inhibitor Brefeldin A affected the expression and secretion of IL-21. Furthermore, a significant correlation between miR-155 and pathological features of AS patients was found.
MOLECULAR BIOLOGY REPORTS
(2023)
Article
Dentistry, Oral Surgery & Medicine
Sara Alijani, Farnoush Fotovat, Loghman Rezaei Soufi, Behnaz Alafchi, Mohammad Hossein Mohammadkhani
Summary: This study compared the shear bond strength (SBS) of stainless steel (SS) orthodontic brackets to PMMA temporary restorative material fabricated by 3D-printing, CAD/CAM technology, and the conventional technique, after surface treatment by sandblasting and laser. Results showed significant differences in SBS among the three fabrication methods in both laser and sandblasting surface treatment groups.
INTERNATIONAL ORTHODONTICS
(2023)
Article
Primary Health Care
Amirhossein Fathi, Sara Rahnama, Sogol Alesaeidi, Elnaz Mousavi, Nazila Bagherboum, Mahnaz GHolami, Farnoush Fotovat
Summary: This study aimed to evaluate the awareness and attitude of pediatric dentists and final-year dental students about dental treatment for children under general anesthesia (GA). A total of 150 participants were randomly selected and a questionnaire was used to assess their awareness and attitude. The results showed that male dentists had a higher level of awareness compared to female dentists, and there was a significant difference in awareness among different age groups. Therefore, appropriate educational methods are needed to improve the awareness and attitude of children's dentists.
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE
(2023)
Article
Biochemistry & Molecular Biology
Hamed Hosseinalizadeh, Omid Mohamadzadeh, Mohammad Saeed Kahrizi, Zahra Razaghi Bahabadi, Daniel J. J. Klionsky, Hamed Mirzei
Summary: GBM is a highly aggressive primary brain tumor that has a high mortality rate in adults. TRIM8, a member of the TRIM protein family, is abnormally expressed in high-grade gliomas and is associated with poor clinical prognosis. It functions as a double-edged sword in glioblastoma development by selectively regulating multiple cellular signaling pathways and stem cell properties. This review provides a detailed analysis of TRIM8 in GBM and its involvement in essential signaling pathways and stem cell-related processes.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2023)